POS1099 QUALITY OF LIFE, WORK IMPAIRMENT, AND DAILY ACTIVITY IMPAIRMENT OF PATIENTS WITH PSORIASIS VERSUS PSORIATIC ARTHRITIS: A REAL-WORLD SURVEY IN US AND EUROPE
Authors: J. F. Merola, L. E. Kristensen, F. Yang, S. Peterson, R. Teneralli, N. Massey, S. D. Chakravarty, M. Hughes, M. Shawi, S. Weatherby, C. Contre, I. Lin, F. Hassan, M. E. Husni
Journal: Annals of the Rheumatic Diseases (2022)

Background Psoriasis (PsO) and psoriatic arthritis (PsA) and are chronic immune-mediated diseases characterised by joint inflammation and skin lesions which negatively impact patients’ health-related quality of life (HRQoL). Several previous comparative studies have focused on PsA patients with or without skin involvement. Better understanding of the impact of both PsO and PsA on HRQoL and work / activity impairment will improve understanding of the incremental burden of PsA compared to PsO, and may lead to more personalised treatment options. Objectives To compare HRQoL, work impairment, and daily activity impairment of patients with a PsO diagnosis (dx) only, PsO dx with musculoskeletal (MSK) symptoms (sx), PsA dx with active skin sx, and PsA dx without active skin sx. Methods Data were drawn from the Adelphi PsO &amp; PsA Disease Specific Programmes™ (DSP), real-world point-in-time surveys of rheumatologists, dermatologists and their consulting patients in the United States and Europe (France, Germany, Italy, Spain and UK); conducted in 2018/19. Patients were grouped according to their symptoms and confirmed diagnoses, comprising four groups: 1. Patients with PsO dx only, 2. Patients with PsO dx and with MSK sx, 3. Patients with PsA dx and with active skin sx, 4. Patients with PsA dx with no active skin sx, Multivariate linear regression analyses with marginal mean predictions examined differences in patient-reported outcome measures (PROMs) between the four groups. Measures included HRQoL (EuroQol 5-Dimension 5-Level [EQ-5D Utility] and EuroQoL Visual Analogue Scale [EQ-VAS]), work impairment, and daily activity impairment (Work Productivity and Activity Impairment Questionnaire [WPAI]). Analyses controlled for demographics (age, sex, BMI), comorbidities present in &gt;10% of patients and current treatment class (biologics, csDMARDs, steroids &amp; other). Results 4491 patients were included: Group 1 (n=1833), Group 2 (n=91), Group 3 (n=2451), and Group 4 (n=116). 54% of patients were male, 89% of patients were white, with a mean age of 46.6 years. Demographics were consistent across all patient groups. The model-predicted EQ-5D-Utility was lower in Groups 2, 3 and 4, compared with Group 1 (p=0.003, p&lt;0.001 and p=0.004 respectively). Similarly, predicted EQ-VAS was lower in Group 3 compared with Group 1 (p=0.006), Table 1. Table 1. Predictions of PROMs for PsO-PsA patient groups PRO tool Group [n]* Predicted PRO value Population norm (MCID ) Regression model p-value (vs. reference group ) EQ-5D Utility score (n=1839) 1 (ref) [743] 0.922 0.88 (0.07) 2 [32] 0.816 0.003 3 [1023] 0.810 &lt;0.001 4 [41] 0.850 0.004 EQ-VAS (n=1882) 1 (ref) [763] 78.78 78.2 (n/a) 2 [36] 70.56 0.057 3 [1040] 73.89 0.006 4 [43] 75.23 0.248 WPAI % overall work impairment (n=1015) 1 (ref) [422] 15.36 n/a (15.0) 2 [14] 17.86 0.560 3 [558] 22.16 &lt;0.001 4 [21] 26.09 0.014 WPAI % work time missed (n=1028) 1 (ref) [424] 0.91 n/a (n/a) 2 [14] 3.57 0.486 3 [569] 4.46 0.002 4 [21] 10.43 0.003 WPAI % impairment while working (n=1153) 1 (ref) [486] 14.90 n/a (20.0) 2 [18] 13.89 0.846 3 [626] 19.63 &lt;0.001 4 [23] 17.39 0.435 WPAI % activity impairment (n=1818) 1 (ref) [732] 18.02 n/a (20.0) 2 [32] 26.25 0.122 3 [1012] 26.14 &lt;0.001 4 [42] 25.24 0.044 *n values provided for reference, but margins are predictions as a result of the model and not for the specific number of patients in each subgroup. (1) patients with PsO dx only (2) Patients with PsO dx and MSK sx (3) Patients with PsA dx and with active skin sx (4) Patients with PsA dx with no active skin sx Overall work impairment increased in Groups 3 and 4, compared with Group 1 (p&lt;0.001 and p=0.014 respectively). Furthermore, Groups 3 and 4 missed more work compared with Group 1 (p=0.002 and p=0.003 respectively). Group 3 patients exhibited an increase in presenteeism and activity impairment compared with Group 1 (p&lt;0.001), Table 1. Conclusion Patients experiencing PsA dx or MSK sx experienced an additional disease burden compared to patients with PsO sx alone, as measured by worse HRQoL and work impairment. Disclosure of Interests Joseph F. Merola Consultant of: Merck Research Laboratories, Abbvie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma, Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals, Consultant of: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals, Grant/research support from: Novo, UCB, Eli Lilly; Novartis and Abbvie, Feifei Yang Employee of: Employee of Janssen Pharmaceuticals, Steve Peterson Employee of: Employee of Janssen Pharmaceuticals, Rachel Teneralli Employee of: Employee of Janssen Pharmaceuticals, Nicola Massey Employee of: Adelphi Real World, Soumya D. Chakravarty Employee of: Employee of Janssen Pharmaceuticals, Megan Hughes Employee of: Adelphi Real World, May Shawi Employee of: Employee of Janssen Pharmaceuticals, Sarah Weatherby Employee of: Adelphi Real World, Christine Contre Employee of: Employee of Janssen Pharmaceuticals, Iris Lin Employee of: Employee of Janssen Pharmaceuticals, Fareen Hassan Employee of: Employee of Janssen Pharmaceuticals, M Elaine Husni Consultant of: Abbvie, Amgen, Eli Lilly, Novartis, Janssen, UCB, Pfizer, Regeneron, and BMS